dc.creator | Rikos D., Dardiotis E., Aloizou A.-M., Siokas V., Zintzaras E., Hadjigeorgiou G.M. | en |
dc.date.accessioned | 2023-01-31T09:51:31Z | |
dc.date.available | 2023-01-31T09:51:31Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.7916/d8-0f2v-aq62 | |
dc.identifier.issn | 21608288 | |
dc.identifier.uri | http://hdl.handle.net/11615/78511 | |
dc.description.abstract | Background: Randomized controlled trials (RCTs) are the cornerstone of modern medical research, and their reporting may not always be optimal. The Consolidated Standards of Reporting Trials (CONSORT) statement is an evidence-based means to improve the quality of RCTs’ reporting by providing a checklist of recommended items. The aim of this study was to assess the reporting quality of published RCTs on the restless legs syndrome (RLS), based on a checklist arising from the CONSORT statement. Methods: Medical electronic databases were searched for RCTs involving patients with RLS. Inclusion criteria were follows: articles must have been published in English and RLS patients must have been randomized into a minimum of two treatment cohorts of different medicinal orientations. CONSORT-recommended items were marked as “reported” or “not reported,” and an overall CONSORT compliance metric was calculated. Comparisons among different time periods, CONSORT-endorsing and non-endorsing, and different levels of impact factor journals were made. Results: Fifty-four eligible trials, published in 21 different scientific journals, were found. The average CONSORT compliance score was 56.6% (23.68–84.21%). CONSORT-endorsing journals had a mean CONSORT compliance of 58.47%, whereas non-endorsing journals had a mean CONSORT compliance of 50.4%. The median CONSORT compliance for articles published in low- (IF<2), medium- (IF 2-7), and high-ranked (IF>7) journals was 52.63, 56.57, and 59.21%, respectively. Only 14 of the 38 CONSORT items (36.8%) were reported in >75% of the articles. Discussion: This study shows that the reporting of RLS-related RCTs is suboptimal, regardless of the time period, the quality of the publishing journal, and the endorsing or non-endorsing of the CONSORT statement. © 2019 Rikos et al. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Tremor and Other Hyperkinetic Movements | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069814445&doi=10.7916%2fd8-0f2v-aq62&partnerID=40&md5=6948c0997720f4e29add8edd9981b4b9 | |
dc.subject | amfebutamone | en |
dc.subject | cabergoline | en |
dc.subject | gabapentin | en |
dc.subject | gabapentin enacarbil | en |
dc.subject | oxycodone | en |
dc.subject | pergolide | en |
dc.subject | pramipexole | en |
dc.subject | pregabalin | en |
dc.subject | ropinirole | en |
dc.subject | rotigotine | en |
dc.subject | Article | en |
dc.subject | drug therapy | en |
dc.subject | health service | en |
dc.subject | human | en |
dc.subject | outcome assessment | en |
dc.subject | polysomnography | en |
dc.subject | priority journal | en |
dc.subject | public health | en |
dc.subject | quality of life | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | restless legs syndrome | en |
dc.subject | bibliometrics | en |
dc.subject | checklist | en |
dc.subject | journal impact factor | en |
dc.subject | publishing | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | research | en |
dc.subject | restless legs syndrome | en |
dc.subject | Bibliometrics | en |
dc.subject | Checklist | en |
dc.subject | Humans | en |
dc.subject | Journal Impact Factor | en |
dc.subject | Publishing | en |
dc.subject | Randomized Controlled Trials as Topic | en |
dc.subject | Research Report | en |
dc.subject | Restless Legs Syndrome | en |
dc.subject | Center for Digital Research and Scholarship | en |
dc.title | Reporting quality of randomized controlled trials in restless legs syndrome based on the CONSORT statement | en |
dc.type | journalArticle | en |